This study examines the use of chemotherapy drugs, capecitabine and temozolomide, after surgery for patients with high-risk pancreatic neuroendocrine tumors (pNETs). These drugs aim to stop cancer cells from growing or spreading. The study compares two groups: one group receives the drugs, and the other group is just observed without any treatment.
- Participants will be involved in the study for up to 5 years, with follow-ups every 6 months for the first 3 years.
- In the treatment group, the drugs are taken by mouth over 14 days in a 28-day cycle, repeated up to 4 times.
- There are risks of side effects from the treatment, but the study will also monitor safety and tolerability.
To join, participants must have had their tumor removed recently and meet specific health criteria. They will need to be able to swallow pills and undergo scans like CT or MRI. People with uncontrolled infections or other cancers are not eligible. The study requires informed consent, meaning participants agree to join with an understanding of potential risks and benefits.
How understandable was the trial content above?
Hard to understand
Easy to understand